Overview
Axsome Therapeutics, Inc., based in the United States, operates within the pharmaceutical industry, focusing predominantly on the development of novel therapies for central nervous system (CNS) disorders. Key projects include AXS-05, which is under development for multiple CNS conditions including major depressive disorder and Alzheimer’s disease agitation. The company also advances AXS-07, designed for the acute treatment of migraine, and AXS-12, aimed at managing symptoms of narcolepsy. Through a combination of unique molecular approaches and clinical strategies, Axsome seeks to address complex medical needs effectively, enhancing therapeutic benefits and treatment accessibility for patients suffering from serious neurological conditions.
Basic Stats
The share price of Axsome Therapeutics, Inc. as of September 5, 2025 is $125.17 / share. This is an increase of 3.21% from the prior week. The market cap (or net worth) of Axsome Therapeutics, Inc. as of September 5, 2025 is $6,235.38 MM.
The Factor Analysis chart (below right) shows a view of Axsome Therapeutics, Inc. from a variety of lenses. Each factor shows how well the company ranks against all other companies in the Fintel global investing universe. Factor scores range from zero to 100, with 100 being most desirable, and 50 being average.
For example, a company with a Value Score of 100 would be the most undervalued company in our database. A company with a Value Score of zero would be the most overvalued.
| Market Cap | 6,235.38 MM |
| EV | 6,119.91 MM |
| Shares Out. | 49.82 MM |
| Earnings Date | |
| EPS (TTM) | -4.96 |
| Dividend Yield | |
| Ex-Dividend Date | |
| Borrow Rate | 0.25 |
| Short Shares Avail. | 0.70 MM |
| Short Interest | 3.72 MM |
| Short Float | 8.86 % |
| Days to Cover | 7.68 days |
| Risk Free Rate | 4.17 % |
| Price Change (1 yr) | 33.60 % |
| Volatility (1 yr) | 0.45 |
| Beta | 1.02 |
| Sharpe Ratio (1 yr) | 0.65 |
| Sortino Ratio (1 yr) | 1.33 |
| PE Ratio | -25.25 |
| Price/Book | 85.33 |
| Price/TBV | 360.43 |
| Book/Market | 0.01 |
| EBIT/EV | -0.04 |
| EBIT(3yr avg)/EV | -0.04 |
| ROA | -0.45 |
| ROE | -2.40 |
| ROIC | -0.86 |
| CROIC | -0.04 |
| OCROIC | -0.42 |
| Implied Volatility | 40.29 % |
| Put/Call OI Ratio | 0.63 |
Factor Scores range from 0 to 100, with 100 being most desirable. Larger circles are better. In situations where we have no data (e.g. no insider trades), we plot the score at 50 to avoid penalizing companies. However, a company that does not pay dividends will get a Dividend Score of Zero. Additionally, we inverted volatility to create a "stability" metric which is better when higher.
Price Target
The average one-year price target for Axsome Therapeutics, Inc. is $179.18. The forecasts range from a low of $145.44 to a high of $210.00. A stock’s price target is the price at which analysts consider it fairly valued with respect to its projected earnings and historical earnings. Analysts typically set price targets that correspond to their buy or sell recommendations.
Update Frequency: Monthly
Stock Upgrades/Downgrades
This card shows analyst upgrades/downgrades for Axsome Therapeutics, Inc.. An analyst rating is a classification that gives investors a sense of analyst sentiment about the direction and performance of an equity - usually a stock - over a period of time, typically 12 months.
The standard analyst ratings are generally as follows:
- Buy/Overweight/Outperform - Any of these ratings conveys an analyst’s belief that the stock is likely to outperform a market index (e.g. the S&P 500).
- Hold/Equal-Weight/Market Perform - Any of these ratings conveys an analyst’s belief that the stock is likely to perform in line with a market index.
- Sell/Underweight/Underperform - Any of these ratings suggest that an analyst believes the stock is likely to underperform a market index.
When an analyst upgrades a stock, they are signaling that the company’s fundamentals are being undervalued by investors. It could also mean they believe the market is underestimating the company’s potential. The opposite is true when a stock receives a downgrade.
The average rating of each individual analyst’s rating is the consensus rating for a stock. This gives investors a broader sense of the overall sentiment for that stock.
| Date | Analyst | Prior | Latest Recommendation |
Action |
|---|---|---|---|---|
| 2022-12-23 | BTIG | Buy | Maintains | |
| 2022-11-29 | SVB Leerink | Outperform | Maintains | |
| 2022-11-29 | Morgan Stanley | Equal-Weight | Maintains | |
| 2022-11-11 | Guggenheim | Buy | Maintains | |
| 2022-11-09 | Mizuho | Buy | Maintains | |
| 2022-11-08 | Morgan Stanley | Equal-Weight | Maintains | |
| 2022-11-01 | Loop Capital | Buy | Initiate | |
| 2022-10-14 | Morgan Stanley | Equal-Weight | Maintains | |
| 2022-10-14 | Guggenheim | Buy | Maintains | |
| 2022-09-30 | Morgan Stanley | Equal-Weight | Maintains | |
| 2022-09-30 | Jefferies | Buy | Maintains | |
| 2022-08-30 | Morgan Stanley | Equal-Weight | Maintains | |
| 2022-08-23 | HC Wainwright & Co. | Buy | Maintains | |
| 2022-08-22 | SVB Leerink | Outperform | Maintains | |
| 2022-08-10 | Morgan Stanley | Equal-Weight | Maintains | |
| 2022-07-08 | Morgan Stanley | Equal-Weight | Maintains | |
| 2022-06-29 | Cowen & Co. | Outperform | Maintains | |
| 2022-06-29 | Cantor Fitzgerald | Overweight | Maintains | |
| 2022-05-03 | Mizuho | Buy | Maintains | |
| 2022-04-27 | Morgan Stanley | Equal-Weight | Maintains | |
| 2022-03-29 | Jefferies | Buy | Maintains | |
| 2022-03-02 | SVB Leerink | Outperform | Maintains | |
| 2021-11-09 | SVB Leerink | Outperform | Maintains | |
| 2021-08-30 | HC Wainwright & Co. | Buy | Maintains | |
| 2021-08-10 | Truist Securities | Buy | Maintains | |
| 2021-08-10 | SVB Leerink | Outperform | Maintains | |
| 2021-08-10 | Morgan Stanley | Overweight | Equal-Weight | Downgrade |
| 2021-08-10 | Mizuho | Buy | Maintains | |
| 2021-06-10 | Berenberg | Buy | Initiate | |
| 2021-05-26 | Morgan Stanley | Overweight | Maintains | |
| 2021-04-27 | HC Wainwright & Co. | Buy | Maintains | |
| 2021-03-02 | Morgan Stanley | Overweight | Maintains | |
| 2021-01-08 | Jefferies | Buy | Initiate | |
| 2020-12-16 | Mizuho | Buy | Initiate | |
| 2020-11-09 | Morgan Stanley | Overweight | Maintains | |
| 2020-09-29 | B of A Securities | Underperform | Initiate | |
| 2020-09-10 | Morgan Stanley | Overweight | Initiate | |
| 2020-04-28 | HC Wainwright & Co. | Buy | Maintains | |
| 2020-04-28 | Cantor Fitzgerald | Overweight | Maintains | |
| 2020-04-14 | Cowen & Co. | Outperform | Initiate | |
| 2019-12-30 | H.C. Wainwright | Buy | Maintains | |
| 2019-12-30 | Cantor Fitzgerald | Overweight | Reiterate | |
| 2019-12-16 | Guggenheim | Buy | Maintains | |
| 2019-12-16 | Cantor Fitzgerald | Overweight | Maintains | |
| 2019-10-16 | Guggenheim | Buy | Initiate | |
| 2019-09-18 | William Blair | Outperform | Initiate | |
| 2019-04-08 | SVB Leerink | Outperform | Initiate | |
| 2019-03-21 | Cantor Fitzgerald | Overweight | Overweight | Maintains |
| 2018-06-07 | H.C. Wainwright | Buy | Initiate | |
| 2017-05-19 | BTIG Research | Buy | Initiate | |
| 2015-12-17 | Brean Capital | Buy | Initiate | |
| 2023-01-05 | Piper Sandler | Neutral | Initiate | |
| 2023-01-30 | Mizuho | Buy | Maintains | |
| 2023-02-14 | B of A Securities | Underperform | Reiterate | |
| 2023-02-14 | HC Wainwright & Co. | Buy | Reiterate | |
| 2023-03-06 | HC Wainwright & Co. | Buy | Reiterate | |
| 2023-02-28 | Guggenheim | Buy | Maintains | |
| 2023-02-28 | Morgan Stanley | Equal-Weight | Maintains | |
| 2023-03-01 | Mizuho | Buy | Maintains | |
| 2023-03-13 | Mizuho | Buy | Reiterate | |
| 2023-03-20 | HC Wainwright & Co. | Buy | Maintains | |
| 2023-04-12 | Morgan Stanley | Equal-Weight | Maintains | |
| 2023-04-17 | HC Wainwright & Co. | Buy | Reiterate | |
| 2023-05-09 | Guggenheim | Buy | Maintains | |
| 2023-05-09 | Cantor Fitzgerald | Overweight | Reiterate | |
| 2023-05-09 | Morgan Stanley | Equal-Weight | Maintains | |
| 2023-05-11 | HC Wainwright & Co. | Buy | Buy | Reiterate |
| 2023-05-11 | Mizuho | Buy | Buy | Maintains |
| 2023-06-12 | Morgan Stanley | Equal-Weight | Equal-Weight | Maintains |
| 2023-06-12 | Mizuho | Buy | Buy | Reiterate |
| 2023-06-14 | Mizuho | Buy | Buy | Reiterate |
| 2023-06-15 | Guggenheim | Buy | Buy | Reiterate |
| 2024-02-16 | Mizuho | Buy | Buy | Maintains |
| 2024-02-06 | UBS | Buy | Initiate | |
| 2023-06-22 | Cantor Fitzgerald | Overweight | Overweight | Reiterate |
| 2023-07-17 | HC Wainwright & Co. | Buy | Buy | Maintains |
| 2024-02-27 | Mizuho | Buy | Buy | Maintains |
| 2023-11-07 | Cantor Fitzgerald | Overweight | Overweight | Reiterate |
| 2023-08-22 | Cantor Fitzgerald | Overweight | Overweight | Reiterate |
| 2023-12-13 | Citigroup | Buy | Initiate | |
| 2023-12-20 | Cantor Fitzgerald | Overweight | Overweight | Reiterate |
| 2023-09-25 | Mizuho | Buy | Buy | Reiterate |
| 2023-08-28 | Mizuho | Buy | Buy | Reiterate |
| 2023-08-11 | Mizuho | Buy | Buy | Maintains |
| 2023-08-08 | B of A Securities | Underperform | Neutral | Upgrade |
| 2023-08-08 | HC Wainwright & Co. | Buy | Buy | Maintains |
| 2023-08-08 | Piper Sandler | Neutral | Overweight | Upgrade |
| 2024-01-16 | Piper Sandler | Overweight | Overweight | Maintains |
| 2023-12-12 | HC Wainwright & Co. | Buy | Buy | Reiterate |
| 2024-03-19 | Baird | Outperform | Initiate | |
| 2024-03-20 | HC Wainwright & Co. | Buy | Buy | Reiterate |
| 2024-01-22 | Cantor Fitzgerald | Overweight | Overweight | Reiterate |
| 2024-06-05 | RBC Capital | Outperform | Outperform | Maintains |
| 2024-04-02 | HC Wainwright & Co. | Buy | Buy | Maintains |
| 2024-03-26 | Truist Securities | Buy | Buy | Maintains |
| 2024-03-26 | RBC Capital | Outperform | Outperform | Maintains |
| 2024-03-26 | Citigroup | Buy | Buy | Maintains |
| 2024-03-26 | HC Wainwright & Co. | Buy | Buy | Maintains |
| 2024-05-07 | Citigroup | Buy | Buy | Maintains |
| 2024-05-07 | Baird | Outperform | Outperform | Maintains |
| 2024-05-07 | HC Wainwright & Co. | Buy | Buy | Reiterate |
| 2023-12-26 | HC Wainwright & Co. | Buy | Buy | Reiterate |
| 2024-03-04 | HC Wainwright & Co. | Buy | Buy | Reiterate |
| 2024-04-10 | Cantor Fitzgerald | Overweight | Overweight | Reiterate |
| 2024-01-25 | RBC Capital | Outperform | Initiate | |
| 2024-02-21 | RBC Capital | Outperform | Outperform | Maintains |
| 2024-02-21 | Guggenheim | Buy | Buy | Maintains |
| 2024-02-21 | Cantor Fitzgerald | Overweight | Overweight | Maintains |
| 2024-02-20 | Cantor Fitzgerald | Overweight | Overweight | Reiterate |
| 2024-05-08 | Mizuho | Buy | Buy | Maintains |
| 2024-03-28 | Mizuho | Buy | Buy | Maintains |
| 2024-04-29 | Morgan Stanley | Equal-Weight | Overweight | Upgrade |
| 2024-06-06 | HC Wainwright & Co. | Buy | Buy | Reiterate |
| 2024-06-12 | Mizuho | Buy | Buy | Reiterate |
| 2024-09-06 | Cantor Fitzgerald | Overweight | Overweight | Reiterate |
| 2025-02-10 | Leerink Partners | Outperform | Outperform | Maintains |
| 2024-07-26 | Cantor Fitzgerald | Overweight | Overweight | Reiterate |
| 2024-08-06 | RBC Capital | Outperform | Outperform | Maintains |
| 2024-08-06 | HC Wainwright & Co. | Buy | Buy | Maintains |
| 2024-08-06 | B of A Securities | Neutral | Buy | Upgrade |
| 2024-08-06 | Needham | Buy | Buy | Reiterate |
| 2024-08-05 | Needham | Buy | Buy | Reiterate |
| 2024-12-12 | Cantor Fitzgerald | Overweight | Overweight | Reiterate |
| 2024-07-18 | B of A Securities | Neutral | Neutral | Maintains |
| 2025-04-29 | RBC Capital | Outperform | Outperform | Maintains |
| 2024-11-12 | Needham | Buy | Buy | Reiterate |
| 2024-09-20 | Cantor Fitzgerald | Overweight | Overweight | Reiterate |
| 2024-09-03 | Wells Fargo | Overweight | Initiate | |
| 2024-12-30 | Needham | Buy | Buy | Reiterate |
| 2024-09-16 | Cantor Fitzgerald | Overweight | Overweight | Reiterate |
| 2025-02-11 | Deutsche Bank | Buy | Initiate | |
| 2025-02-11 | B of A Securities | Buy | Buy | Maintains |
| 2025-02-11 | Mizuho | Outperform | Outperform | Maintains |
| 2025-02-11 | HC Wainwright & Co. | Buy | Buy | Reiterate |
| 2024-07-22 | RBC Capital | Outperform | Outperform | Reiterate |
| 2024-07-22 | Needham | Buy | Initiate | |
| 2025-02-27 | Morgan Stanley | Overweight | Overweight | Maintains |
| 2024-12-31 | Mizuho | Outperform | Outperform | Maintains |
| 2024-08-22 | HC Wainwright & Co. | Buy | Buy | Reiterate |
| 2024-09-05 | Needham | Buy | Buy | Reiterate |
| 2024-08-06 | UBS | Buy | Buy | Maintains |
| 2024-11-13 | Baird | Outperform | Outperform | Maintains |
| 2024-11-13 | Needham | Buy | Buy | Reiterate |
| 2025-04-03 | HC Wainwright & Co. | Buy | Buy | Reiterate |
| 2025-02-20 | HC Wainwright & Co. | Buy | Buy | Maintains |
| 2025-02-24 | Needham | Buy | Buy | Reiterate |
| 2024-12-31 | HC Wainwright & Co. | Buy | Buy | Reiterate |
| 2025-02-12 | Wells Fargo | Overweight | Overweight | Maintains |
| 2025-03-27 | Mizuho | Outperform | Outperform | Maintains |
| 2024-11-27 | HC Wainwright & Co. | Buy | Buy | Reiterate |
| 2025-01-31 | HC Wainwright & Co. | Buy | Buy | Maintains |
| 2025-05-07 | HC Wainwright & Co. | Buy | Buy | Maintains |
| 2025-01-21 | HC Wainwright & Co. | Buy | Buy | Reiterate |
| 2025-01-06 | Needham | Buy | Buy | Reiterate |
| 2024-10-04 | RBC Capital | Outperform | Outperform | Maintains |
| 2024-11-25 | HC Wainwright & Co. | Buy | Buy | Reiterate |
| 2025-01-29 | RBC Capital | Outperform | Outperform | Maintains |
| 2024-09-05 | HC Wainwright & Co. | Buy | Buy | Reiterate |
| 2025-02-25 | HC Wainwright & Co. | Buy | Buy | Reiterate |
| 2025-03-06 | HC Wainwright & Co. | Buy | Buy | Reiterate |
| 2025-02-03 | RBC Capital | Outperform | Outperform | Maintains |
| 2025-02-03 | Truist Securities | Buy | Buy | Maintains |
| 2025-02-03 | Mizuho | Outperform | Outperform | Maintains |
| 2024-09-09 | Cantor Fitzgerald | Overweight | Overweight | Reiterate |
| 2025-05-22 | HC Wainwright & Co. | Buy | Buy | Reiterate |
| 2025-03-03 | Needham | Buy | Buy | Reiterate |
| 2025-03-03 | Baird | Outperform | Outperform | Maintains |
| 2025-01-13 | Needham | Buy | Buy | Reiterate |
| 2025-01-13 | Truist Securities | Buy | Buy | Maintains |
| 2025-02-26 | Mizuho | Outperform | Outperform | Maintains |
| 2025-02-10 | Needham | Buy | Buy | Reiterate |
| 2025-02-19 | Cantor Fitzgerald | Overweight | Overweight | Reiterate |
| 2025-02-19 | RBC Capital | Outperform | Outperform | Maintains |
| 2025-02-19 | Truist Securities | Buy | Buy | Maintains |
| 2025-02-19 | Needham | Buy | Buy | Maintains |
| 2025-04-01 | Needham | Buy | Buy | Reiterate |
| 2025-04-07 | Jefferies | Buy | Initiate | |
| 2025-06-12 | RBC Capital | Outperform | Outperform | Maintains |
| 2025-06-09 | Needham | Buy | Buy | Maintains |
| 2025-05-06 | Wells Fargo | Overweight | Overweight | Maintains |
| 2025-05-06 | Baird | Outperform | Outperform | Maintains |
| 2025-06-10 | HC Wainwright & Co. | Buy | Buy | Reiterate |
| 2025-06-03 | Oppenheimer | Outperform | Initiate | |
| 2025-08-05 | B of A Securities | Buy | Buy | Maintains |
| 2025-08-05 | RBC Capital | Outperform | Outperform | Maintains |
| 2025-08-04 | Needham | Buy | Buy | Reiterate |
